166 related articles for article (PubMed ID: 15755007)
1. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma.
Dunder I; Berker B; Atabekoglu C; Bilgin T
Eur J Gynaecol Oncol; 2005; 26(1):79-82. PubMed ID: 15755007
[TBL] [Abstract][Full Text] [Related]
2. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
Fennelly D; Aghajanian C; Shapiro F; O'Flaherty C; McKenzie M; O'Connor C; Tong W; Norton L; Spriggs D
J Clin Oncol; 1997 Jan; 15(1):187-92. PubMed ID: 8996141
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients.
Akizuki S; Katsumata N; Yamanaka Y; Andoh M; Fujiwara Y; Watanabe T
Int J Clin Oncol; 2005 Aug; 10(4):272-5. PubMed ID: 16136374
[TBL] [Abstract][Full Text] [Related]
5. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer.
Ghamande S; Lele S; Marchetti D; Baker T; Odunsi K
Int J Gynecol Cancer; 2003; 13(2):142-7. PubMed ID: 12657114
[TBL] [Abstract][Full Text] [Related]
6. Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience.
Watari H; Hosaka M; Mitamura T; Moriwaki M; Ohba Y; Todo Y; Takeda M; Ebina Y; Sakuragi N
Eur J Gynaecol Oncol; 2008; 29(6):573-7. PubMed ID: 19115681
[TBL] [Abstract][Full Text] [Related]
7. 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer.
Ishikawa H; Nakanishi T; Nawa A; Suzuki Y; Kuzuya K
Int J Clin Oncol; 2001 Jun; 6(3):128-31. PubMed ID: 11706781
[TBL] [Abstract][Full Text] [Related]
8. First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
Zylberberg B; Dormont D; Madelenat P; Daraï E
Eur J Gynaecol Oncol; 2004; 25(3):327-32. PubMed ID: 15171311
[TBL] [Abstract][Full Text] [Related]
9. Weekly paclitaxel infusion as salvage therapy in ovarian cancer.
Boruta DM; Fowler WC; Gehrig PA; Boggess JF; Walton LA; Van Le L
Cancer Invest; 2003; 21(5):675-81. PubMed ID: 14628424
[TBL] [Abstract][Full Text] [Related]
10. Single agent paclitaxel in resistant and relapsed epithelial ovarian cancer after first-line platinum-based chemotherapy--experience in an Asian population.
Tay SK; Thilagam MD
Ann Acad Med Singap; 1998 Sep; 27(5):645-9. PubMed ID: 9919333
[TBL] [Abstract][Full Text] [Related]
11. Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study.
Nishio S; Ota S; Sugiyama T; Matsuo G; Kawagoe H; Kumagai S; Ushijima K; Nishida T; Kamura T
Int J Clin Oncol; 2003 Feb; 8(1):45-8. PubMed ID: 12601542
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T
Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151
[TBL] [Abstract][Full Text] [Related]
13. Weekly 1 hour paclitaxel infusion in patients with recurrent gynecological tumors: a pilot study.
Ota S; Sugiyama T; Komai K; Hirai N; Kumagai S; Ushijima K; Nishida T; Kamura T
Jpn J Clin Oncol; 2001 Aug; 31(8):395-8. PubMed ID: 11574633
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
Rosenberg P; Andersson H; Boman K; Ridderheim M; Sorbe B; Puistola U; Parö G
Acta Oncol; 2002; 41(5):418-24. PubMed ID: 12442916
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients.
Oliverio G; Canuti D; Tononi A; Scarpellini M; Panzini I; Galli I; Ravaioli A
J Chemother; 1999 Aug; 11(4):301-5. PubMed ID: 10465133
[TBL] [Abstract][Full Text] [Related]
17. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
Havrilesky LJ; Alvarez AA; Sayer RA; Lancaster JM; Soper JT; Berchuck A; Clarke-Pearson DL; Rodriguez GC; Carney ME
Gynecol Oncol; 2003 Jan; 88(1):51-7. PubMed ID: 12504627
[TBL] [Abstract][Full Text] [Related]
18. [Weekly paclitaxel infusion in patients with recurrent ovarian cancer--a pilot study].
Kawagoe H; Kawata T; Nishio S; Shimomura T; Fujiyoshi K; Ishimatsu J; Tsunawaki A
Gan To Kagaku Ryoho; 2003 Jan; 30(1):151-4. PubMed ID: 12557722
[TBL] [Abstract][Full Text] [Related]
19. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer.
Kita T; Kikuchi Y; Takano M; Suzuki M; Oowada M; Konno R; Yamamoto K; Inoue H; Seto H; Yamamoto T; Shimizu K
Gynecol Oncol; 2004 Mar; 92(3):813-8. PubMed ID: 14984946
[TBL] [Abstract][Full Text] [Related]
20. Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.
Sharma R; Graham J; Blagden S; Gabra H
BMC Cancer; 2011 Jul; 11():289. PubMed ID: 21745358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
